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Resistance to cytotoxic drugs is thought to be amajor cause of treatment failure in childhood
neuroblastoma, and members of the ATP-binding cassette (ABC) transporter superfamily
may contribute to this phenomenon by active efﬂux of chemotherapeutic agents from
cancer cells. As a member of the C subfamily of ABC transporters, multidrug resistance-
associated protein MRP4/ABCC4 has the ability to export a variety of endogenous and
exogenous substances across the plasmamembrane. In light of its capacity for chemother-
apeutic drug efﬂux, MRP4 has been studied in the context of drug resistance in a number
of cancer cell types. However, MRP4 also inﬂuences cancer cell biology independently
of chemotherapeutic drug exposure, which highlights the potential importance of endoge-
nous MRP4 substrates in cancer biology. Furthermore, MRP4 is a direct transcriptional
target of Myc family oncoproteins and expression of this transporter is a powerful inde-
pendent predictor of clinical outcome in neuroblastoma. Together, these features suggest
that inhibition of MRP4 may be an attractive therapeutic approach for neuroblastoma and
other cancers that rely on MRP4. In this respect, existing options for MRP4 inhibition
are relatively non-selective and thus development of more speciﬁc anti-MRP4 compounds
should be a major focus of future work in this area.
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INTRODUCTION
Neuroblastoma, a cancer which arises from primitive cells of the
sympathetic nervous system is the most common extra cranial
solid tumor to occur in children. More than 50% of cases present
as high risk disease, for which long-term survival rates remain
below 50% (Brodeur, 2003; Maris et al., 2007). Within the last
decade, considerable effort has been made toward universal risk
stratiﬁcation for neuroblastoma patients with a view to better tai-
loring of treatment. A recent international review of 8,800 patients
throughout 1990–2002 conﬁrmed patient age at diagnosis, tumor
stage, DNA ploidy, chromosome 11q status, and MYCN status
as important parameters to consider for patient risk stratiﬁca-
tion (Cohn et al., 2009). Detected in 20% of neuroblastoma cases,
ampliﬁcation of the MYCN proto-oncogene at chromosome 2p24
is one of the prominent indicators of aggressive clinical disease,
reduced progression-free survival, and poor outcome (Maris et al.,
2007). Consequently, the MYCN oncogene has been characterized
extensively and in mice, its targeted expression toward neuroec-
todermal cells drives the development of neuroblastoma (Weiss
et al., 1997). However, speciﬁc target genes regulated by MYCN
and their contributions to an aggressive phenotype are still largely
unknown. The C subfamily of the ATP-binding cassette (ABC)
family of transporters, also known as the multidrug resistance-
associated protein (MRP) family, consists of nine members, many
of which are known for their roles in chemotherapeutic drug
efﬂux. Of these, ABC subfamily C member 1 (ABCC1), ABCC3,
andABCC4 are direct transcriptional targets of MYCNand expres-
sion levels of each of these genes are independent prognostic
factors for neuroblastoma (Norris et al., 1996, 2005; Haber et al.,
2006; Porro et al., 2010; Henderson et al., 2011). Although ABC
transporter genes are classically known for their contributions to
drug resistance there has been growing evidence of their effects
in neuroblastoma biology independent of drug efﬂux (Fletcher
et al., 2010; Henderson et al., 2011). In this review, we examine the
potential role of ABCC4 in the malignant phenotype of neurob-
lastoma and other cancers and consider the potential beneﬁts of
targeting the MRP4 protein.
THE MRP4 EFFLUX PUMP
MRP4 is a member of the C subfamily of ABC transporters. ABC
transporters are mostly transmembrane proteins that mediate the
ATP-dependent movement of a range of substances across cel-
lular membranes (Russel et al., 2008). Located on chromosome
13q32.1, the ABCC4 gene encodes the shortest member of the
ABCC/MRP family (Russel et al., 2008) and mediates efﬂux of a
variety of exogenous and endogenous molecules (Table 1).
Studies using Abcc4 gene knockout mice have begun to demon-
strate the physiological role of MRP4, particularly in the liver,
brain, and kidney. During cholestatic injury, where bile ﬂow is
obstructed from the liver, Abcc4 was up-regulated in rats and
mice after bile duct ligation (Wagner et al., 2003; Denk et al.,
2004) and also in patients with progressive familial intrahepatic
cholestasis (Keitel et al., 2005). Mrp4 mediates the glutathione-
dependent efﬂux of bile acids and its induction under these
conditions is a protective response to guard against liver necro-
sis (Mennone et al., 2006; Rius et al., 2006). In addition to the
removal of metabolites, Mrp4 is able to protect vital structures
in vivo against various xenobiotics through active drug efﬂux
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Table 1 | Drug and endogenous substrates of MRP4.
Exogenous substances Endogenous substances
Pharmacological
class
Drug Structural
class
Endogenous
Folic acid
derivative
Leucovorin Cyclic and
ADP
nucleotides
cGMP
cAMP
ADP
DNA
topoisomerase
inhibitor
Topotecan*
Irinotecan* (SN38)1
Purine
analogs
Urate
Eicosanoids PGE1
PGE2
PGF2α
Anti-viral Adefovir† Folates Folic acid
PMEA2† Bile acids Cholate
Ceftizoxime Cholytaurine
Tenofovir†
Anti-metabolite 6-Mercaptopurine3† Conjugated
steroids
DHEAS
E217βG
Methotrexate
PMEA, para-methoxyethylamphetamine; PG, prostaglandin; cGMP, cyclic-
guanosine monophosphate; cAMP, cyclic-adenosine monophosphate; ADP,
adenosine diphosphate; DHEAS, dehydroepiandrosterone; E217βG, estradiol-
17-β-D-glucuronide.
Table modiﬁed from Russel et al. (2008).
1Norris et al., 2005
2Schuetz et al., 1999
3Janke et al., 2008
*Relevant to neuroblastoma treatment; camptothecins.
†Nucleotide and nucleoside analog drugs.
(Table 1). Abcc4-deﬁcient mice exhibit reduced renal excretion
of the anti-viral drugs adefovir and tenofovir (Imaoka et al., 2007)
and of the anticancer drug, topotecan (Leggas et al., 2004). Con-
sequently, the levels of topotecan in the plasma and some tissues
are elevated. Abcc4 deﬁciency also allows topotecan to cross the
blood brain barrier and to penetrate the central nervous sys-
tem and brain (Leggas et al., 2004). In addition, Abcc4 knockout
mice had enhanced accumulation of the anti-viral drug9-(2-
phosphonylmethoxyethyl)- adenine (PMEA) in the bone marrow,
thymus, spleen, and intestine compared to wild-type littermates
(Belinsky et al., 2007). Mrp4 is also known to be highly expressed
in myeloid progenitor cells and has been shown to protect these
cells against thiopurine-induced hematopoietic toxicity through
active efﬂux (Krishnamurthy et al., 2008). Together, these stud-
ies highlight MRP4 as a versatile transporter able to protect vital
organs against the accumulation of biological metabolites and
a variety of xenobiotics, from anti-viral to chemotherapeutic
drugs.
SIGNALING SUBSTRATES OF MRP4
In addition to protecting cells against metabolic products and
xenobiotics, MRP4 mediates transport of various endogenous
bioactive substances (Table 1). Notably, a number of signal-
ing molecules with established roles in normal tissue function
and tumor biology are MRP4 substrates and these include cyclic
nucleotides, prostaglandins, and leukotrienes (Chen et al., 2001;
Reid et al., 2003; Rius et al., 2008).
Cyclic adenosine monophosphate (cAMP) plays a critical role
as an intracellular second messenger, mediating a range of cellu-
lar functions. For example, cAMP-mediated signaling promotes
monocyte differentiation (Giordano et al., 2003). Interestingly,
ABCC4 expression levels decrease with the differentiation toward
mature leukocytes (Oevermann et al., 2009), which could pro-
mote cAMP accumulation and hence the strength of signaling
down differentiation pathways. In cardiomyocytes, MRP4 reg-
ulates cAMP homeostasis which in turn controls the activity
of key properties such as cardiac performance and structure
(Sassi et al., 2011). Elevation of intracellular cAMP also pro-
motes morphological differentiation and decreases proliferation
in cultured neuroblastoma cell lines (Prasad et al., 2003; Sanchez
et al., 2004).
In addition to supporting the normal development of vari-
ous tissues, signaling molecules exported by MRP4 are able to
support tumor growth in a variety of cancers. As mediators of
the cyclooxygenase pathway, prostaglandins support an inﬂam-
matory microenvironment and can promote cell proliferation
and survival in tumor cells, including neuroblastoma (Rasmu-
son et al., 2012). In addition, prostaglandin-E2 (PGE2) secreted
from neuroblastoma cells can facilitate interactions with tumor-
supportive bone marrow stromal cells (Ara et al., 2009). Clinical
observations and mouse models have demonstrated the impor-
tance of prostaglandin-mediated pathways in colorectal cancer.
Increased levels of PGE2 are reported in human colorectal adeno-
mas and carcinomas compared to paired normal mucosa (Pugh
and Thomas, 1994). Furthermore, clinical studies have shown that
adenomadevelopment in familial adenomatous polyposis patients
can be prevented by inhibiting prostaglandin production (Chell
et al., 2006). Conversely, mouse models have shown direct evi-
dence of prostaglandin-promoted tumor growth, with an increase
in tumor incidence following PGE2 treatment in ApcMin/+ mice
(Greenhough et al., 2009).
Signaling via leukotrienes, another class of substrates trans-
ported by MRP4, promotes cell survival and proliferation through
the activation of both autocrine and paracrine pathways. Up-
regulation of leukotrienes in various cancers is thought to stimu-
late epithelial and surrounding stromal cells to produce relevant
growth factors, pro-inﬂammatory mediators, and angiogenic
factors which provide a tumor-supportive microenvironment
(Wang and DuBois, 2010). In neuroblastoma cells, prolonged
exposure to leukotriene B4 leads to increased cell viability in SK-
N-BE(2)-C cells, while inhibitors of leukotriene production or
signaling lead to cell cycle arrest and apoptosis (Sveinbjornsson
et al., 2008).
MRP4 AND DRUG RESISTANCE IN CANCER
Chemotherapy resistance is a major obstacle to successful cancer
treatment and members of the ABCC/MRP transporter fam-
ily are perhaps best known for their abilities to confer drug
resistance through the active export of structurally dissimilar
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chemotherapeutic compounds in various cancers (Borst et al.,
2000). Clinically relevant drugs known to be transported by MRP4
include nucleoside and nucleotide analogs (Chen et al., 2001) and,
relevant to neuroblastoma, the camptothecins irinotecan (Norris
et al., 2005) and topotecan (Tian et al., 2005) (Table 1). Therefore,
the role of MRP4 in establishing drug resistance has been explored
in a number of cancer cell lines.
HepG2 cells transfected with the human ABCC4 plasmid
showed enhanced resistance to irinotecan, topotecan, and
cyclophosphamide, all of which are used in neuroblastoma treat-
ment or are in trial for use (Langler et al., 2002; Kushner et al.,
2006; London et al., 2010). Using established MRP4 inhibitors
such as MK571 and celecoxib, resistance to these cytotoxic agents
was signiﬁcantly reduced (Tian et al., 2005, 2006). Resistance to
irinotecan and reduction in its intracellular accumulation was
additionally shown in HEK-293 cells transfected with the human
ABCC4 plasmidwhen compared toparentalHEK-293 cells (Norris
et al., 2005).
Expression of MRP4 in leukemia cells correlated with drug
resistance to relevant chemotherapeutic agents used in leukemia
treatment. A fourfold increase in MRP4 expression was observed
in CEM-MP5 leukemia cells, which were selected for resistance
through step-wise exposure to 6-mercaptopurine (6-MP). Com-
pared to the parental CEM cell line, CEM-MP5 cells displayed
a 100-fold greater resistance to 6-MP (Peng et al., 2008). Addi-
tionally, the acute myeloid leukemia (AML) cell line K562/ADR
showed elevated expression of MRP4 compared to parental
K562, which had a greater resistance to adriamycin, a stan-
dard chemotherapy for AML. Although there is no evidence
of direct efﬂux of adriamycin by MRP4, knockdown of MRP4
through lentiviral-mediated shRNAwithin the K562/ADR cell line
enhanced adriamycin-induced apoptosis (Liu et al., 2012), sug-
gestingMRP4may contribute drug resistance byothermeans, such
as removal of toxic metabolites associated with drug exposure.
In the gastric cancer cell line SGC7901/DDP, resistance to
cisplatin was developed through incremental cisplatin exposure
and was associated with increased MRP4 expression. This resis-
tance was reversed upon siRNA-mediated MRP4 knockdown
(Zhang et al., 2010). Although cisplatin is not an MRP4 sub-
strate, the elevation of MRP4 might promote cell survival through
increased in export of autocrine signaling molecules involved in
regeneration, such as various nucleotides or prostanoids (Alek-
sunes et al., 2008).
MRP4, AN INDEPENDENT PROGNOSTIC FACTOR IN
NEUROBLASTOMA
In attempt to gain insight into the potential clinical relevance
of MRP4, the relationship between expression, pathology, and
patient outcome has been examined in several tumor types. To
address this question in neuroblastoma, in two independent
studies, quantitative reverse transcriptase-PCR was used to deter-
mine ABCC4 expression levels in primary neuroblastoma tumors
obtained prior to treatment (Norris et al., 2005; Henderson et al.,
2011). In both studies, ABCC4 expression was associated with
MYCN ampliﬁcation as well as advanced tumor stage. Inter-
estingly, chromatin immunoprecipitation and luciferase reporter
assays were used to demonstrate that MRP4 expression is directly
regulated by the MYCN and MYC oncogenes (Porro et al., 2010),
raising the possibility that MYCN induction of ABCC4 expression
may contribute to the malignant phenotype driven by MYCN in
neuroblastoma.
More importantly, ABCC4 expression in primary neuroblas-
toma is strongly associated with reduced event-free survival and
overall survival and multivariate analysis revealed that ABCC4
expression retained prognostic signiﬁcance following adjustment
for tumor stage, age, and MYCN ampliﬁcation (Henderson et al.,
2011). Analysis of a microarray dataset from a third indepen-
dent cohort of patients enrolled in the German Neuroblastoma
Trial NB90-NB2004 conﬁrmed these ﬁndings (Oberthuer et al.,
2006; Henderson et al., 2011). For none of the three cohorts
however, were any of the chemotherapeutic agents used to treat
patients substrates of MRP4, suggesting the link between MRP4
and poor patient outcome is not attributable to resistance mech-
anisms related to drug efﬂux. Furthermore, expression of ABCC4
was determined in primary untreated neuroblastoma tumors indi-
cating that ABCC4 expression levels were independent of prior
treatment exposure. These observations suggested that enhanced
MRP4 expression contributes to poor outcome in neuroblastoma
through mechanisms other than facilitation of drug export. In
support of this, siRNA-mediated knockdown of MRP4 in the neu-
roblastoma cell lines SK-N-BE(2)C and SH-SY-5Y reduced cell
proliferation and clonogenicity (Henderson et al., 2011). These
studies indicate MRP4 expression may be an important biologi-
cal factor in neuroblastoma, outside of its ability to contribute to
drug efﬂux. Studies currently in progress involving cross breeding
between MYCN transgenic mice and Abcc4 gene knockout mice
will further assess the biological impact of MRP4 inneuroblastoma
development, progression, and treatment response.
MRP4 IN OTHER CANCERS
While deﬁnitive studies are yet to be reported, some evidence
suggests MRP4 may be important in the biology of other can-
cers. In addition to playing a role in drug-resistant leukemia cell
lines, MRP4 appears to regulate leukemia cell proliferation and
differentiation independently of drug efﬂux through the endoge-
nous MRP4 substrate cAMP. Blockage of MRP4 through shRNA
or the MRP4 inhibitor, probenecid, in the human leukemia
cell line U937 caused intracellular accumulation of cAMP and
consequent leukemic maturation toward a more differentiated
phenotype (Copsel et al., 2011). These ﬁndings are consistent with
the apparent role for MRP4 and cAMP-mediated signaling in nor-
mal hematopoietic cell development, where ABCC4 expression
levels decrease during differentiation toward mature leukocytes
(Oevermann et al., 2009). Other studies suggest a vital role for
MRP4 in T-cell migration, where inhibition of MRP4, either by
viral shRNA or sildenaﬁl, impaired the abilities of interstitial den-
dritic cells to migrate toward lymph node chemokines (van deVen
et al., 2008), raising the possibility that MRP4 could also inﬂuence
migratory properties of either cancer cells or their neighbors.
Polymorphisms within the ABCC4 gene are associated with
poor outcome in acute lymphoblastic leukemia. Persons with
the C-allele of the TC-1393 polymorphism, which may inﬂuence
ABCC4 gene promoter activity, had longer event-free survival
and persons with the A-allele of the CA-934 polymorphism had
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reduced event-free survival compared to the respective other geno-
types. Despite the CA-934 polymorphism, the level of MRP4
expression within the liver and amount of 6-MP accumula-
tion in the kidney remained unchanged, suggesting the CA-934
polymorphism does not contribute a drug resistant phenotype
within this patient cohort (Ansari et al., 2009). Although themech-
anism underlying CA-934 polymorphism and poor outcome is
unknown, the efﬂux of an endogenous substrate is one potential
mechanism.
MRP4 protein was more abundant in pancreatic cancers when
compared to adjacent non-cancerous pancreatic tissue and knock-
down of MRP4 using shRNA in two pancreatic cancer cell
lines, Panc1 and BxPC-3, inhibited cell growth and clonogenic-
ity through cell cycle arrest (Zhang et al., 2011). These initial
ﬁndings suggest that MRP4 could contribute to pancreatic can-
cer progression, however, the underlying mechanism responsible
for the observed cell cycle arrest and reduction in cell proliferation
during MRP4 knockdown is currently unknown.
Androgens are steroidal hormones required for normal prostate
development and are also important signalingmolecules in driving
prostate cancer. Upon androgen binding, the androgen receptor
translocates into the nucleus where it binds to androgen response
elements in androgen-responsive genes, including various genes
involved in cell proliferation and apoptosis (Heinlein and Chang,
2004). Using oligonucleotide gene array analysis, two groups inde-
pendently identiﬁed ABCC4 to be one such androgen regulated
gene (Cai et al., 2006; Ho et al., 2008). Due to increased andro-
gen signaling, MRP4 expression is higher in prostate cancers than
in normal prostate cells (Suzuki et al., 2003; Ho et al., 2008). Anti-
androgen treatment using bicalutamide reducedMRP4 expression
in the LnCAP prostate cancer cell line and tumors from patients
treated with androgen ablation pre-operatively were found to have
lower levels of MRP4 expression compared to those from uncas-
trated prostate cancer patients. Despite MRP4 being a potentially
important target of the androgen receptor, no correlation was
seen between MRP4 expression and known prognostic factors or
relapse free survival (Ho et al., 2008).
Despite these observations and the association between MRP4
expression and drug resistance in various cancer cell lines, few
studies have adequately explored the relationship between MRP4
expression and clinical outcome in these cancers, and, with the
exception of neuroblastoma, no association has been reported
(Steinbach et al., 2003; Zhang et al., 2011). Future studies in appro-
priate in vitro and tumor models, together with large prospective
studies of tumor specimens to examine associations between gene
expression and clinical outcome are required to follow-up these
suggestive observations.
TARGETING MRP4 FOR THE TREATMENT OF
NEUROBLASTOMA
In neuroblastoma, given the strong association between MRP4
expression and poor clinical outcome, the effects on cancer
cell biology, and the use of MRP4 cytotoxic substrates such
as topotecan in relapsed neuroblastoma patients (Saylors et al.,
2001; Langler et al., 2002; London et al., 2010), treatment through
MRP4 inhibition may provide a novel approach to inﬂuence both
treatment efﬁcacy and tumor growth.
Table 2 | MRP4 inhibitors and their selectivity.
MRP4 inhibitor Mode of action/
structural class
Additional targets
Dipyridamole Nucleoside transport inhibition P-gp, MRP1
Sildenaﬁl PDE5 inhibitor MDR1, BCRP
MK571 Leukotriene antagonist MRP1, MRP2, MRP5
Indomethacin Non-steroidal anti-inﬂammatory MRP1, MRP2
Celecoxib COX-2 inhibitor MRP1
Probenecid Organic anion MRP2, MRP3
Sulindac Non-steroidal anti-inﬂammatory MRP2
Losartan Angiotensin II type I receptor
antagonist
P-gp
Quercetin Flavonoid MRP1, MRP2, MRP5
Table modiﬁed from Russel et al. (2008).
P-gp, P-glycoprotein; MRP,multidrug resistance protein; PDE, phosphodiesterase;
COX, cyclooxygenase
A number of pharmacological agents with MRP4 inhibitory
activity have been identiﬁed. However, most are non-speciﬁc and
are able to target otherABC transporter familymembers (Table 2).
Experience from early clinical trials using inhibitors of the mul-
tidrug transporter P-glycoprotein (P-gp/MDR1) indicates that
future generations of inhibitors should be selective if the beneﬁt of
targeting MRP4 is to be effectively realized (Szakacs et al., 2006).
Such inhibitors should block transport of the relevant exogenous
or endogenous substrates, thus identiﬁcation of key physiolog-
ical substrates should be a focus of future work. Screening for
selective MRP4 small molecule inhibitors may allow for the devel-
opment of a more targeted approach for neuroblastoma therapy
and better treatment strategies for othermalignancies, particularly
if patients whose tumors have high levels of MRP4 are selected for
intervention.
Small molecule inhibitors are able to inhibit the function of
speciﬁc proteins through a number of mechanisms. These include
binding DNA at various gene promoters, thereby inhibiting gene
expression at either the transcriptional or translational level,
through to inhibiting protein–substrate interaction through com-
petitive binding or inducing a protein conformational change (Yap
et al., 2012). High-throughput screens commonly involve rapidly
testing tens of thousands of potential drug candidates in target-
based or cell-based assays with the aim of identifying potentially
active compounds from large compound collections (Macarron
et al., 2011). Small molecule inhibitors have the advantage of being
efﬁciently produced and further developed in order to inhibit
relevant oncogenic targets (Bleicher et al., 2003). Such screening
methods led todevelopment of Imatinib (Glivec),which is a potent
inhibitor of the Abl tyrosine kinase and selectively kills leukemia
cells expressing the Bcr-Abl oncogene (Druker et al., 1996). With
a high response rate to therapy and a favorable cytotoxic proﬁle
compared to standard chemotherapy this compound and its rela-
tives represent an incredible breakthrough in therapy for chronic
myelogenous leukemia and other Philadelphia chromosome-
positive leukemias (O’Brien et al., 2003; Novak, 2004).
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High-throughput screening of chemical libraries has been
used successfully to identify novel inhibitors of ABC transporters
(Burkhart et al., 2009). A library of 2,300 analogs based upon
P-gp modulators was screened for MRP1 inhibition through a
cell-based readout system. The breast cancer cell line MCF7/VP16,
which has ampliﬁed MRP1 levels but low P-gp levels was trans-
duced with a p53-responsive LacZ reporter to create a read out of
MRP1 inhibition during accumulation of doxorubicin, a cytotoxic
MRP1 substrate. Based on these screening efforts, six structural
scaffolds which effectively inhibit MRP1 were identiﬁed (Burkhart
et al., 2009).
Similarly, we have developed high-throughput screening
methodology for MRP4 inhibitors using MRP4-over express-
ing HEK-293 cells which exhibit sixfold resistance to the MRP4
cytotoxic substrate 6-MP. From 30,000 random chemical small
molecules we were able to identify 19 “hit” compounds able to
reverse the resistance of MRP4-overexpressing HEK-293 cells to 6-
MP, and to cause intracellular 6-MP accumulation. Remarkably, in
the absence of drug exposure, two of the compounds also recapitu-
lated the effects of siRNA-mediatedMRP4 knockdown in that they
inhibited growth of the neuroblastoma cell line, SK-N-BE(2)C,
and this was accompanied by extension of neuritic processes,
consistent with enhanced morphological differentiation. Each of
the compounds has a distinct chemical structure and screen-
ing of structural analogs has identiﬁed additional anti-MRP4
compounds suitable for pre-clinical testing.
One potential problemwith hits derived fromhigh-throughput
screening, however, may arise if the compounds do not have a
single molecular target (Bleicher et al., 2003). Understanding the
complete spectrum of intracellular targets of a novel inhibitor
will identify potential toxicities and facilitate prediction of cancer
behavior toward a particular inhibitor. Given the high structural
homology and substrate overlap of MRP4 with other ABC trans-
porter proteins, such as MRP1, MRP5, and ABCG2 (Borst et al.,
2000; Klaassen and Aleksunes, 2010), it is essential to screen
for speciﬁc MRP4 inhibitors in order to limit potential off tar-
get effects. To overcome this issue, candidate inhibitors can be
tested on cell lines overexpressing a range of ABC transporters,
each paired with their respective parental control, in the pres-
ence of cytotoxic substrate relevant to each transporter in order
to determine the speciﬁcity of inhibitors (Burkhart et al., 2009).
Additionally, inside-out vesicle assays can also be used to char-
acterize ABC transporter substrate speciﬁcity and the effects on
of inhibitors on transporter-mediated excretion of individual
substrates (Schlemmer and Sirotnak, 1994; Loe et al., 1996).
CONSIDERATIONS AND FUTURE DIRECTIONS
MRP4 offers a valuable and novel target for the treatment of neu-
roblastoma and potentially other malignancies for which evidence
implicates MRP4 in cancer biology and chemotherapy resistance.
With speciﬁcMRP4 inhibitors, it is expected that side effectswould
be minimal given MRP4 knock-out mice do not show any obvious
abnormalities (Belinsky et al., 2007). However, drug distribution
to various organ compartments and potential toxicities of MRP4
inhibitors in combination with established chemotherapies must
be considered and their effects proﬁled in combination with rel-
evant chemotherapeutics in appropriate preclinical models. A
potential beneﬁt from the role of MRP4 in biodistribution lies in
the possibility that MRP4 inhibitors may enhance drug availability
to tumor tissues through uptake across the blood brain barrier or
reduced renal elimination. This may be particularly beneﬁcial for
drugs in clinical trials for the treatment of neuroblastoma such as
irinotecan and topotecan and, as suitable cohorts emerge, this pos-
sibility should be explored by examining the relationship between
clinical outcome and MRP4 expression in primary tumors of neu-
roblastoma patients receiving these drugs (Kushner et al., 2006;
Simon et al., 2007). Furthermore, the ability to examine pharma-
cological inhibition of MRP4 using in vitro and in vivo models will
offer a tool with which to gain greater insight into its role in the
transcriptional program of MYCN in neuroblastoma.
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